Sezary Syndrome Market Trends

Growth Drivers

• Rise In the Number of Clinical Trials Associated with The Disease - University College London and Merck Sharp & Dohme LLC have been conducting Phase II clinical trials since January 2019. The study aims to assess the effectiveness of Pembrolizumab combined with radiotherapy for patients with relapsed or refractory mycosis fungoides/Sezary syndrome.
• Emergence of Novel Treatments for Sézary Syndrome - An antibody therapy called mogamulizumab targets a protein called CC chemokine receptor (CCR4) for the treatment of Sézary syndrome. Skin-cell lymphoma cells commonly contain this protein. National Institute for Health and Care Excellence will assess whether the treatment is eligible for NHS funding.
• A Rise in Biomarker Research and Development - In the early 21st century, regulations in the field of biomarkers developed rapidly and are closely linked to the development of personalized medicine, which involves tailoring treatment based on the genetic and epigenetic characteristics of an individual. This has enabled a better understanding of Sezary Syndrome and the ability to diagnose and treat the condition more effectively.

Challenges

• Difficulty of diagnosing and treating syndrome- Sezary Syndrome is a rare form of skin cancer that is often difficult to diagnose due to its vague symptoms. Additionally, treatments for Sezary Syndrome are often complicated, expensive, and not always effective, which can limit the market growth for treatments.
• Lack of awareness of the condition in emerging economies
• Limited research and approved treatments available for the disease